Population Pharmacokinetics of Hydroxychloroquine in Patients with Rheumatoid Arthritis

Therapeutic Drug Monitoring

Volumn 25, Issue 6, 2003, Pages 671-681

  Carmichael, Samantha J ^a,b   Charles, Bruce ^a   Tett, Susan E ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b WESTERN INFIRMARY   (United Kingdom)

Author keywords

Bioavailability; Hydroxychloroquine; NONMEM; Population pharmacokinetics; Rheumatoid arthritis

Indexed keywords

ANTIMALARIAL AGENT; ANTIRHEUMATIC AGENT; HYDROXYCHLOROQUINE; METHOTREXATE;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; COMPARTMENT MODEL; CONCENTRATION RESPONSE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL AVAILABILITY; DRUG INTERACTIONS; FEMALE; HUMANS; HYDROXYCHLOROQUINE; MALE; METHOTREXATE; MIDDLE AGED; MODELS, BIOLOGICAL;

EID: 0344630191     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200312000-00005     Document Type: Article

References (24)

1. Richter JA, Runge LA, Pinals RS, et al. Analysis of treatment terminations with gold and antimalarial compounds in rheumatoid arthritis. J Rheumatol. 1980;7:153-159.
2. Shipley M, Silman A. Should patients on hydroxychloroquine have their eyes examined regularly? Br J Rheumatol. 1997;36:514-515.
3. Blyth C, Lane C. Hydroxychloroquine retinopathy: is screening necessary? BMJ. 1998;316:716-717.
4. May K, Metcalf T, Gough A. Screening for hydroxychloroquine retinopathy. Screening should be selective. BMJ. 1998;317:1388-1389.
5. Kremer JM. Rational use of new and existing disease-modifying agents in rheumatoid arthritis. Ann Intern Med. 2001;134:695-706.
6. Choi HK, Seeger JD, Kuntz KM. A cost-effectiveness analysis of treatment options for patients with methotrexate-resistant rheumatoid arthritis. Arthritis Rheum. 2000;43:2316-2327.
7. O'Dell JR, Haire CE, Erikson N, et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med. 1996; 334:1287-1291.
8. O'Dell JR. Triple therapy with methotrexate, sulfasalazine, and hydroxychloroquine in patients with rheumatoid arthritis. Rheum Dis Clin North Am. 1998;24:465-477.
9. Tett S, McLachlan A, Day R, et al. Insights from pharmacokinetic and pharmacodynamic studies of hydroxychloroquine. Agents Actions [Suppl]. 1993;44: 145-190.
10. Tett SE, Cutler DJ, Day RO, et al. A dose-ranging study of the pharmacokinetics of hydroxychloroquine following intravenous administration to healthy volunteers. Br J Clin Pharmacol. 1988;26: 303-313.
11. Tett S, Cutler D, Day R. Antimalarials in rheumatic diseases. Baillieres Clin Rheumatol. 1990;4:467-489.
12. Kitridou RC, Solomon SD. The patient with rheumatoid arthritis. Am Fam Physician. 1971;4:109-116.
13. Furst DE, Lindsley H, Bacthge B, et al. Dose-loading with hydroxychloroquine improves the rate of response in early, active rheumatoid arthritis: a randomized, double-blind six-week trial with eighteen-week extension. Arthritis Rheum. 1999;42:357-365.
14. McLachlan AJ, Tett SE, Cutler DJ, et al. Bioavailability of hydroxychloroquine tablets in patients with rheumatoid arthritis. Br J Rheumatol. 1994;33:235-239.
15. Tett SE, Cutler DJ, Day RO. Bioavailability of hydroxychloroquine tablets assessed with deconvolution techniques. J Pharm Sci. 1992;81:155-159.
16. Tett SE, Day RO, Cutler DJ. Concentration-effect relationship of hydroxychloroquine in rheumatoid arthritis - a cross sectional study. J Rheumatol. 1993;20:1874-1879.
17. Tett SE, Cutler DJ, Beck C, et al. Concentration-effect relationship of hydroxychloroquine in patients with rheumatoid arthritis - a prospective, dose ranging study. J Rheumatol. 2000;27:1656-1660.
18. Ropes MW, Bennett GA, Cobb S. Revision of diagnostic criteria for rheumatoid arthritis. Bull Rheum Dis. 1958;9:175-176.
19. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315-324.
20. Tett SE, Cutler DJ, Brown KF. High-performance liquid chromatographic assay for hydroxychloroquine and metabolites in blood and plasma, using a stationary phase of poly(styrene divinylbenzene) and a mobile phase at pH 11, with fluorimetric detection. J Chromatogr. 1985;344:241-248.
21. Gabrielsson J, Weiner D. Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications, 2nd ed. SP Society. 1997, Stockholm: Swedish Pharmaceutical Press.
22. Miller DR, Fiechtner JJ, Carpenter JR, et al. Plasma hydroxychloroquine concentrations and efficacy in rheumatoid arthritis. Arthritis Rheum. 1987;30: 567-571.
23. Laaksonen AL, Koskiahde V, Juva K. Dosage of anti-malarial drugs for children with juvenile rheumatoid arthritis and systemic lupus erythematosus. A clinical study with determination of serum concentrations of chloroquine and hydroxychloroquine. Scand J Rheumatol. 1974;3:103-108.
24. McLachlan AJ, Tett SE, Cutler DJ, et al. Bioavailability and in vivo dissolution of hydroxychloroquine in fed volunteers. Br J Clin Pharmacol. 1993;36:405-411.